These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 8613951)

  • 21. Apparent mechanism-based inhibition of human CYP3A in-vitro by lopinavir.
    Weemhoff JL; von Moltke LL; Richert C; Hesse LM; Harmatz JS; Greenblatt DJ
    J Pharm Pharmacol; 2003 Mar; 55(3):381-6. PubMed ID: 12724045
    [TBL] [Abstract][Full Text] [Related]  

  • 22. In vitro metabolism of trazodone by CYP3A: inhibition by ketoconazole and human immunodeficiency viral protease inhibitors.
    Zalma A; von Moltke LL; Granda BW; Harmatz JS; Shader RI; Greenblatt DJ
    Biol Psychiatry; 2000 Apr; 47(7):655-61. PubMed ID: 10745059
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Protease inhibitors as inhibitors of human cytochromes P450: high risk associated with ritonavir.
    von Moltke LL; Greenblatt DJ; Grassi JM; Granda BW; Duan SX; Fogelman SM; Daily JP; Harmatz JS; Shader RI
    J Clin Pharmacol; 1998 Feb; 38(2):106-11. PubMed ID: 9549640
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Potent mechanism-based inhibition of human CYP3A in vitro by amprenavir and ritonavir: comparison with ketoconazole.
    von Moltke LL; Durol AL; Duan SX; Greenblatt DJ
    Eur J Clin Pharmacol; 2000 Jun; 56(3):259-61. PubMed ID: 10952482
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Oxidative metabolism of amprenavir in the human liver. Effect of the CYP3A maturation.
    Tréluyer JM; Bowers G; Cazali N; Sonnier M; Rey E; Pons G; Cresteil T
    Drug Metab Dispos; 2003 Mar; 31(3):275-81. PubMed ID: 12584153
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Inhibition of human cytochromes P450 in vitro by ritonavir and cobicistat.
    Hossain MA; Tran T; Chen T; Mikus G; Greenblatt DJ
    J Pharm Pharmacol; 2017 Dec; 69(12):1786-1793. PubMed ID: 28960344
    [TBL] [Abstract][Full Text] [Related]  

  • 27. ABT-378, a highly potent inhibitor of the human immunodeficiency virus protease.
    Sham HL; Kempf DJ; Molla A; Marsh KC; Kumar GN; Chen CM; Kati W; Stewart K; Lal R; Hsu A; Betebenner D; Korneyeva M; Vasavanonda S; McDonald E; Saldivar A; Wideburg N; Chen X; Niu P; Park C; Jayanti V; Grabowski B; Granneman GR; Sun E; Japour AJ; Leonard JM; Plattner JJ; Norbeck DW
    Antimicrob Agents Chemother; 1998 Dec; 42(12):3218-24. PubMed ID: 9835517
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Assessment of CYP3A-mediated drug-drug interaction potential for victim drugs using an in vivo rat model.
    Rioux N; Bellavance E; Bourg S; Garneau M; Ribadeneira MD; Duan J
    Biopharm Drug Dispos; 2013 Oct; 34(7):396-401. PubMed ID: 23873286
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Involvement of multiple cytochrome P450 isoenzymes in drug interactions between ritonavir and direct oral anticoagulants.
    Tamemoto Y; Shibata Y; Hashimoto N; Sato H; Hisaka A
    Drug Metab Pharmacokinet; 2023 Dec; 53():100498. PubMed ID: 37778107
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ritonavir inhibits intratumoral docetaxel metabolism and enhances docetaxel antitumor activity in an immunocompetent mouse breast cancer model.
    Hendrikx JJ; Lagas JS; Song JY; Rosing H; Schellens JH; Beijnen JH; Rottenberg S; Schinkel AH
    Int J Cancer; 2016 Feb; 138(3):758-69. PubMed ID: 26297509
    [TBL] [Abstract][Full Text] [Related]  

  • 31. In vitro and in vivo clinical pharmacology of dimethyl benzoylphenylurea, a novel oral tubulin-interactive agent.
    Rudek MA; Zhao M; Smith NF; Robey RW; He P; Hallur G; Khan S; Hidalgo M; Jimeno A; Colevas AD; Messersmith WA; Wolff AC; Baker SD
    Clin Cancer Res; 2005 Dec; 11(23):8503-11. PubMed ID: 16322314
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Assessment of drug-drug interaction potential and PBPK modeling of CC-223, a potent inhibitor of the mammalian target of rapamycin kinase.
    Tong Z; Narayanan R; Atsriku C; Nissel J; Li Y; Liu H; Wang X; Surapaneni S
    Xenobiotica; 2019 Jan; 49(1):54-70. PubMed ID: 29297772
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Investigating the contribution of CYP2J2 to ritonavir metabolism in vitro and in vivo.
    Kaspera R; Kirby BJ; Sahele T; Collier AC; Kharasch ED; Unadkat JD; Totah RA
    Biochem Pharmacol; 2014 Sep; 91(1):109-18. PubMed ID: 24973543
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clearance and clearance inhibition of the HIV-1 protease inhibitors ritonavir and saquinavir in sandwich-cultured rat hepatocytes and rat microsomes.
    Treijtel N; van Eijkeren JC; Nijmeijer S; de Greef-van der Sandt IC; Freidig AP
    Toxicol In Vitro; 2009 Feb; 23(1):185-93. PubMed ID: 19038324
    [TBL] [Abstract][Full Text] [Related]  

  • 35. CYP450 Enzyme-Mediated Metabolism of TCAS and Its Inhibitory and Induced Effects on Metabolized Enzymes in Vitro.
    Shen G; Wang C; Zhou L; Li L; Chen H; Yu W; Li H
    Int J Environ Res Public Health; 2015 Sep; 12(9):10783-93. PubMed ID: 26404338
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Identification of the cytochrome P450 enzymes involved in the metabolism of cisapride: in vitro studies of potential co-medication interactions.
    Bohets H; Lavrijsen K; Hendrickx J; van Houdt J; van Genechten V; Verboven P; Meuldermans W; Heykants J
    Br J Pharmacol; 2000 Apr; 129(8):1655-67. PubMed ID: 10780971
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Methoxsalen as an in vitro phenotyping tool in comparison with 1-aminobenzotriazole.
    Palacharla RC; Molgara P; Panthangi HR; Boggavarapu RK; Manoharan AK; Ponnamaneni RK; Ajjala DR; Nirogi R
    Xenobiotica; 2019 Feb; 49(2):169-176. PubMed ID: 29382249
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The inhibitory and inducing effects of ritonavir on hepatic and intestinal CYP3A and other drug-handling proteins.
    Loos NHC; Beijnen JH; Schinkel AH
    Biomed Pharmacother; 2023 Jun; 162():114636. PubMed ID: 37004323
    [TBL] [Abstract][Full Text] [Related]  

  • 39. ABT-538 is a potent inhibitor of human immunodeficiency virus protease and has high oral bioavailability in humans.
    Kempf DJ; Marsh KC; Denissen JF; McDonald E; Vasavanonda S; Flentge CA; Green BE; Fino L; Park CH; Kong XP
    Proc Natl Acad Sci U S A; 1995 Mar; 92(7):2484-8. PubMed ID: 7708670
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Metabolic switching of BILR 355 in the presence of ritonavir. I. Identifying an unexpected disproportionate human metabolite.
    Li Y; Lai WG; Whitcher-Johnstone A; Busacca CA; Eriksson MC; Lorenz JC; Tweedie DJ
    Drug Metab Dispos; 2012 Jun; 40(6):1122-9. PubMed ID: 22393120
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.